Delaware journal of public health最新文献

Working from data provided by the Delaware Division of Professional Regulation from May 2022 to September 2023, this 16-month update supports a general rebound in active licensing numbers across the Delaware Healthcare industry in professions licensed through the Division of Professional Regulation's DelPros system. This report articulates the types of data analysis currently available through the data and research initiative of Delaware Health Force, provides a high-level overview of the data, and offers preliminary recommendations based on the data. Overall, the healthcare workforce in Delaware shows a steady rebound, with many license types appearing to reach new highs. There are some areas in which continued loss of active licenses is of concern.

Novel modalities of vaccine will be required to address the current and future public health concerns we face. Many infectious diseases lack clinically approved vaccines causing immense burden to the health care system both domestically and abroad. More concerningly, the prevalence of antimicrobial resistance (AMR) is anticipated to rise over the coming decades and limit our tools to treat these infections. There is thus an urgent need to develop vaccinations to overcome these rising gaps in treatment and prevent infections moving forward. At Nitro Biosciences, we are developing a platform to create next-generation vaccines for diseases currently lacking clinically approved products. By harnessing an expanded genetic code, we can precisely modify antigens to enhance their immunogenicity, enabling a broadening of the scope of antigens to target in vaccine development and enhancing the potential to create efficacious vaccines where other efforts have failed.

To assess the work hours and income of patients who have been diagnosed with cancer, treatable with curative intent. The study evaluated the impact of lost wages on patients and their families in the population that is served by Bayhealth Medical Center.

Methods: This study was conducted between 2016 and 2020. The curative cancer focus included breast, lung, prostate, colorectal, testicular, uterine, cervical, bladder, esophageal, head and neck, and stomach. Patients were identified on their survivorship visit with Medical Oncology or Radiation Oncology. Two surveys were used to collect information specific to employment status, leave of absence/change in hours, and monthly income.

Results: Survey one had 142 participants. Survey two had 134 participants. In survey one, 99.3% of participants reported being employed at least half time at the time of diagnosis. On the Survivorship visit, 95% reported being currently employed at least half time. Only 87% were employed in the same job and title. When reporting income, 64% of participants had the same income, and 25.4% reported a reduction in income since being diagnosed and completing cancer treatment. In survey two, completed one-year post-survivorship visit, 83.6% of participants reported being employed at least half time. Of those, 76.9% were working for the same employer as they were at time of diagnosis. To that end, 26.1% of participants reported their income as lower than it was at time of diagnosis.

Conclusion: A cancer diagnosis with treatment can and does have an impact on a person's ability to remain employed at least half time and sustain the same level of income.

There is an urgent need to engage, educate, and train a skilled workforce for Delaware's growing life science sector. A sizeable number of these jobs can be obtained with a high school diploma or GED, coupled with an industry informed short-term training program. Unfortunately, this is not widely known, and many disadvantaged populations do not have access to the necessary training. Through a partnership between the Delaware Bioscience Association and the Delaware Biotechnology Institute at the University of Delaware, efforts are currently underway to develop a pilot training program, specifically focusing on the skills needed for biomanufacturing and basic laboratory operations. Additionally, the program will devote significant resources to the identification and recruitment of participants with an emphasis on engaging historically underrepresented populations, as well as removing barriers to accessing the training. The goal is to connect talent to available careers in the industry, providing participants with increased economic mobility and financial stability.

This paper proposes a quadrilateral approach to advance biopharmaceutical manufacturing by fostering collaboration among biopharma, lab informatics, healthcare systems, and academia. Through a retrospection based on Gary Pisano's analysis and real-world examples like insitro and Spark Therapeutics, we highlight the imperative of continuous process innovation and regulatory collaboration. We emphasize leveraging technological advancements, particularly in machine learning and artificial intelligence (AI), to catalyze a paradigm shift in drug manufacturing and delivery. The discussion extends to fostering academic and business partnerships, akin to Silicon Valley's ecosystem, and engaging healthcare systems in a more integrated role, exemplified by the advent of point-of-care manufacturing. The paper underscores the unique potential of the State of Delaware to propel forward the biopharma manufacturing space, advocating for a coordinated effort to translate scientific advancements into real healthcare benefits.